| Data set | Procedure | What's in this data set | Panel | Sex | Age (weeks) | Year |
|---|---|---|---|---|---|---|
|
|
study archive | Body, organ, fat pad weights, weight gain, litter size. | QTL population | both | 2-10wks | 2009 |
|
|
organ weights
with high-fat high-sucrose diet |
Heart, liver, gonadal fat pads. | DO population | both | 4-26wks | 2018 |
|
|
organ weights
with high-fat diet |
Skeletal muscle, soleus muscle, heart, kidney, liver, various fat pads. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
organ weights
with high-fat diet |
Cecum, muscles, heart, heart-atria, kidney, liver, spleen, fat pads. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
organ dimensions
with high-fat diet |
Intestine length. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
bottle choice test | Sodium chloride solution taste threshold. Fluid intake. | inbred (13) | m | 7-8wks | 2011 |
|
|
intake monitoring
with sucrose |
Food, caloric, water intake. Baseline and with sucrose (several concentrations). 24h test. | inbred (12) | m | 13-17wks | 2006 |
|
|
health assessment
with Plasmodium berghei |
Susceptibility, Plasmodium berghei (malaria). Parasitemia in blood and distribution in brain, spleen, lungs, liver. | inbred (31) | both | 8-12wks | 2010 |
|
|
study archive | Body, organ weights, litter size, abdominal fat, lipids, insulin, leptin. | QTL population | both | 3-6wks | 2009 |
|
|
study archive | Gut length. | QTL population | both | 2006 | |
|
|
organ weights
with high-fat diet |
Heart, liver, kidney, spleen weights after high-fat diet (17wks) vs. control. | LGXSM w/par (19) | both | 12-16wks | 2004 |
|
|
operant conditioning chamber
with sucrose |
Rewards behavior and learning in a lever-based oral sucrose self-administering system. Daily 8 h sessions for 3 days. | HMDP (91) | m | 7-22wks | 2018 |
|
|
study archive | Colitis susceptibility, severity. Colon histopathology, body and spleen weight. | QTL population | both | 6wks | 2001 |
|
|
organ weights | Heart, liver, spleen weights. | inbred w/CC8 (8) | both | 20-21wks | 2020 |
|
|
histopathology
with ENU |
Tumor growth frequency rates. ENU mutagen 100 mg/kg vs. control. | inbred (20) | both | 9wks; 12-64wks | 2006 |
|
|
bone dimensions | 3D, craniofacial landmark coordinates based on centroid. | DO population | both | 8-60 wks | 2020 |
|
|
organ weights
with isoniazid |
Body, liver, kidney weights. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
lipid profile
with isoniazid |
Cholesterol, triglycerides. Hepatic lipids. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
histopathology
with isoniazid |
Liver pathology scores. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
organ weights
with DB289 |
Kidney and liver weights. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
computed tomography
with P.gingivalis and F.nucleatum |
Susceptibility to periodontitis. Mice infected with P. gingivalis and F. nucleatum vs. control. | CC pre (23) | both | 8wks | 2013 |
|
|
study archive
with high-fat diet |
Lipids, atherosclerosis lesions, parathyroid hormone after high-fat diet. | QTL population | f | 20wks | 2004 |
|
|
observation (SHIRPA) | Behavior, and neurosensory responses (SHIRPA protocol). | KOMP | both | 8-18wks | 2021 |
|
|
X-ray | Counts of vertebrae, ribs, digits, and other categorical parameters. | KOMP | both | 8-18wks | 2021 |
|
|
observation (SHIRPA) | Behavior, and neurosensory responses (SHIRPA protocol). | KOMP | both | 66-81wks | 2021 |
|
|
organ weights | Brain, heart, kidney, liver, spleen weights. | inbred (11) | both | 8, 16 wks | 2006 |
|
|
observation (SHIRPA) | Behavior, and neurosensory responses (SHIRPA protocol). | inbred (6) | m | 10wks | 2010 |
|
|
histopathology
with cadmium |
Cadmium-induced toxicity to liver, testis, trigeminal ganglia. | inbred (8) | m | 8wks | 2001 |
|
|
observation (SHIRPA) | Behavior, and neurosensory responses (SHIRPA protocol). | B6.A consomic w/par (23) | both | 8wks | 2005 |
|
|
study archive
with high-fat diet |
Lipids (plasma), liver weight, gallbladder and gallstone histopathology. | QTL population | m | 16-18wks | 2003 |
|
|
study archive
with high-fat diet |
Lipids (plasma), bile, liver weight, gallbladder and gallstone histopathology. | QTL population | m | 16-18wks | 2003 |
|
|
study archive
with high-fat diet |
Lipids, gallbladder and gallstone histopathology after high-fat diet. | QTL population | m | 14-20wks | 2004 |
|
|
study archive
with high-fat diet |
Gallstone susceptibility. | QTL population | both | 24-26wks | 2005 |
|
|
study archive | Colitis susceptibility. Colon histopathology, spleen weight. | QTL population | both | 6wks | 2002 |
|
|
study archive | Kidney morphology. | QTL population | both | 1-2wks | 2005 |
|
|
lipid profile
with high-fat high-sucrose diet |
Cholesterol, triglycerides. 16h fast, plasma. Hepatic triglycerides. | B6.A consomic w/par (24) | m | 5, 21 wks | 2015 |
|
|
organ weights
with high-fat high-sucrose diet |
Liver weight after 16wks of high-fat high-sucrose diet. 16h fast. | B6.A consomic w/par (24) | m | 5, 21 wks | 2015 |
|
|
lipid profile
with high-fat high-sucrose diet |
Cholesterol and triglycerides. Overnight fast, plasma. Hepatic triglycerides. | inbred (2) | m | 21 wks | 2016 |
|
|
organ weights
with high-fat high-sucrose diet |
Liver weight after 16 wks of high-fat high-sucrose diet. Overnight fast. | inbred (2) | m | 21 wks | 2016 |
|
|
lipid profile
with high-fat diet |
Cholesterol, HDL, non-HDL. 4h fast, plasma. Hepatic lipids. 8wks on high-fat diet. | inbred (44) | both | 15-19wks | 2000 |
|
|
histopathology
with high-fat diet |
Gallstone, gallbladder, and atherosclerosis lesion histopathology after 8wks on high-fat diet. | inbred (44) | both | 15-19wks | 2000 |
|
|
organ dimensions
with high-fat diet |
Gallbladder volume after 8wks on high-fat diet. | inbred (44) | both | 15-19wks | 2000 |
|
|
organ weights
with high-fat diet |
Liver weight after 8wks on high-fat diet. | inbred (44) | both | 15-19wks | 2000 |
|
|
lipid profile
with high-fat diet |
Cholesterol, HDL, non-HDL. 4h fast, plasma. Hepatic lipids. 8wks on high-fat diet. | obesity mutants (8) | both | 15-19wks | 2000 |
|
|
histopathology
with high-fat diet |
Gallstone, gallbladder, and atherosclerosis lesion histopathology after 8wks on high-fat diet | obesity mutants (8) | both | 15-19wks | 2000 |
|
|
organ dimensions
with high-fat diet |
Gallbladder volume after 8wks on high-fat diet | obesity mutants (8) | both | 15-19wks | 2000 |
|
|
organ weights
with high-fat diet |
Liver weight after 8wks on high-fat diet. | obesity mutants (8) | both | 15-19wks | 2000 |
|
|
organ weights | Brain, heart, kidney, liver, pancreas, spleen weights. | B6.129 and 129.B6 consomic w/par (9) | both | 26wks | 2015 |
|
|
study archive | Spleen, liver murine cytomegalovirus study. | QTL population | both | 8-12wks | 2009 |
|
|
organ weights
with high-fat diet and ethanol |
Liver weight after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. | inbred (14) | m | 8-14wks | 2011 |
|
|
histopathology
with high-fat diet and ethanol |
Liver histopathology, injury after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. | inbred (14) | m | 8-14wks | 2011 |
|
|
metabolite quantification
with high-fat diet and ethanol |
Homocysteine concentration after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. | inbred (14) | m | 8-14wks | 2011 |
|
|
lipid profile
with high-fat diet and ethanol |
Hepatic triglycerides after 4wk regimen of ethanol and high-fat diet. 24h fast. | inbred (14) | m | 8-14wks | 2011 |
|
|
RNA expression profiling
with high-fat diet and ethanol |
Liver gene expression after 4wk regimen of ethanol and high-fat diet. 24h fast. mRNA abundance relative to the control (high-fat only) group. | inbred (14) | m | 8-14wks | 2011 |
|
|
organ weights
with trichloroethylene |
Liver, kidney weights. Trichloroethylene-exposed vs. control. | inbred (7) | m | 6-7wks | 2014 |
|
|
drug and metabolite quantification
with trichloroethylene |
Trichloroethylene metabolite in blood, liver, kidney after trichloroethylene exposure. | inbred (7) | m | 6-7wks | 2014 |
|
|
RNA expression profiling
with trichloroethylene |
Trichloroethylene effect on mRNA gene expression in liver and kidney, relative to controls. | inbred (7) | m | 6-7wks | 2014 |
|
|
histopathology
with trichloroethylene |
Kidney histopathology evaluation after trichloroethylene exposure, relative to controls. | inbred (7) | m | 6-7wks | 2014 |
|
|
lipid profile | Cholesterol, triglycerides, free fatty acids, phospholipids. 5h fast, plasma. Hepatic triglycerides. | inbred (11) | both | 8-10wks | 2005 |
|
|
organ weights | Liver weight. | inbred (11) | both | 8-10wks | 2005 |
|
|
biomarker quantification
with high-fat diet |
Bile acid levels in plasma, feces, and liver. | BXD w/par (36) | m | 8-29 wks | 2022 |
|
|
organ weights
with high-fat diet |
Liver, spleen, kidney, fat pads, muscles, cecum. | BXD w/par (36) | m | 8-29 wks | 2022 |
|
|
organ dimensions
with high-fat diet |
Small intestine length. | BXD w/par (36) | m | 8-29 wks | 2022 |
|
|
RNA expression profiling
with selenium |
Selenium regulation of selenoprotein enzyme activity and transcripts. | inbred w/CC8 (8) | m | 3-14wks | 2018 |
|
|
metabolic panel
with acetaminophen |
Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum), liver enzyme homeostasis. Acetaminophen (several doses) vs. control, several timepoints post-Rx. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
histopathology
with acetaminophen |
Liver histopathology, necrosis after acetaminophen vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
metabolite quantification
with acetaminophen |
Liver protein homeostasis. Acetaminophen vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
biomarker quantification
with acetaminophen |
Liver cytochrome isoforms. Acetaminophen vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
organ weights
with acetaminophen |
Liver weight after acetaminophen (several doses) vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
metabolite quantification
with acetaminophen |
Glutathione. | inbred (5) | m | 6-8wks | 2005 |
|
|
histopathology
with acetaminophen |
Liver histopathology, necrosis, injury after acetaminophen vs. control. 18h fast. | inbred (5) | m | 6-8wks | 2005 |
|
|
bottle choice test | Various salt solutions (several concentrations) vs. water. | inbred (28) | m | 9wks | 2001 |
|
|
bottle choice test | Various salt solutions (several concentrations) vs. water. | inbred w/CC7 (40) | both | 9-15wks | 2002 |
|
|
mineral quantification | Liver mineral levels. Iron, copper, zinc. Iron homeostasis. | inbred (18) | both | 8wks | 2010 |
|
|
study archive
with high-fat diet |
Liver weight, gallbladder and gallstone histopathology. | QTL population | both | 18-20wks | 2002 |
|
|
study archive
with high-fat diet |
Lipids (plasma), liver weight, gallbladder and gallstone histopathology. | QTL population | both | 6-16wks | 2003 |
|
|
study archive
with high-fat diet |
Lipids (plasma), liver weight, gallbladder and gallstone histopathology. | QTL population | both | 2005 | |
|
|
metabolite quantification
with arsenic |
iAs quantification in urine and liver, at 24 and 26 wks after iAs exposure. IAs speciation evaluated specifically monomethyl-arsenic acid (MMA) and dimethyl-arsenic acid (DMA) | DO population | m | 4-34 wks | 2022 |
|
|
study archive | Body weight (several timepoints) and liver weight. | QTL population | both | 2-12wks | 2007 |